Submit manuscript...
eISSN: 2471-0016

International Clinical Pathology Journal

Editorial Volume 2 Issue 2

Acute erythroblastic leukemia (AEL): a rare subset of de novo AML with a complex rearrangement involving ETV6 locus and loss of RB1 locus

Head D,1 Zalepa D,1 Hollis A,1 Ashwini Yenamandra1

1Department of Pathology, Immunology and Microbiology, Vanderbilt University Medical Center, Nashville, USA
1Department of Pathology, Immunology and Microbiology, Vanderbilt University Medical Center, Nashville, USA

Correspondence: Ashwini Yenamandra, Medical Director of Clinical Cytogenetics, Assistant Professor, Department of Pathology, Immunology and Microbiology, Vanderbilt University Medical Center 719, Thompson Lane, Nashville, TN 37204, USA

Received: November 30, -0001 | Published: February 25, 2016

citation: Yenamandra A, Hollis A, Zalepa D, et al. Acute erythroblastic leukemia (AEL): a rare subset of de novo AML with a complex rearrangement involving ETV6 locus and loss of RB1 locus. Int Clin Pathol J. 2016;2(2):25–26. DOI: 10.15406/icpjl.2016.02.00032

Download PDF


Acute Erythroid leukemia (AEL) is a rare subset of acute myeloid leukemia (AML). AEL has been reported mostly in adults and comprises less than 5% of AML (WHO, 2008). In addition, AEL has been further divided into erythroid leukemia (erythroid/myeloid) and pure erythroid leukemia.1,2 Pure erythroid leukemia consists of neoplastic proliferation of immature cells that are committed to erythroid lineage has been reported (WHO, 2008). Pure erythroid leukemia can occur at any stage. The genetic abnormalities that have been reported in AEL are similar to those identified in Acute Myeloid leukemia (AML) with myelodysplastic (MDS) changes and consists of complex karyotype with structural abnormalities including -5/del(5q), -7/del(7q), +8 and/or RUNX1 mutations. However, JAK2, FLT3, TP53 and RAS mutations have been reported to be of low incidence in AEL.3 The prognosis has been described unfavorable with complex karyotype.

Cryptic and recurrent rearrangement of t(7;12) involving ETV6 locus has been identified in children of age two years or younger with various types of leukemia. Heterogeneity of the breakpoints ranging from 7q32 (very few) or q36 (frequently) and 12p13 have been reported in myeloid disorders.4–9 We report here a case of Pediatric Acute Erythroblastic Leukemia with a variant t(7;12) translocation involving three chromosomes 5, 7 and 12 with loss of the RB1 locus at 13q14 region of chromosome 13. Sequential metaphase FISH and cytogenetic were performed to identify the partner chromosomes in the ETV6 locus rearrangement.

A two- year old male with a fatigue, bruising, petechiae and fever was presented for evaluation of normocytic anemia and thrombocytopenia in February, 2014. His initial bone marrow (BM) biopsy was hyper cellular, packed with a predominance of erythroids and a large percentage of immature forms. Flow cytometry was positive for CD33, CD7, CD36 and CD71, consistent with erythroid differentiation of immature cells. The diagnosis was FLT3-, NMP1- and KIT17 D816V negative AML. Cytogenetics revealed seventeen of the twenty cells analyzed revealed an abnormal karyotype and three cells were normal. Karyotype was highly complex with 46,XY,der(5)del(5)(p15.1p15.1)t(5;12;7), der(7)t(5;12;7), der(12)del(12)(p13p13)t(5;12;7), del(13)(q12q14)[17]/46,XY[3] with a simultaneous deletion of 5p15.1 and 12p13 regions of derivative chromosome 5 and derivative respectively, along with an interstitial deletion of chromosome 13 from q12q14 region involving the RB1 locus (Figure 1-3). The patient entered remission with induction chemotherapy, received consolidation chemotherapy, and at most recent follow up of about 18months after the initial diagnosis bone marrow studies were negative for leukemia by morphology and cytogenetic.

Figure 1 Abnormal Karyotype.
Figure 2 Deletion of RB1 locus.
Figure 3 ETV6 from 12p13 region moved to 7q.

The variant translocation described here has not been previously reported. The putative disrupted gene in this translocation at 7q32 is unknown. This breakpoint at 7q32 appears to have a better prognosis than translocations involving the 7q36 locus, as most patients with the 7q36 breakpoint have had a poor outcome. This is also the first case report with a deletion of RB1 locus in AEL. A thorough literature search including Mitelman database of Chromosome Aberrations and Gene Fusions in Cancer4–10 did not reveal report of cases with similar complex rearrangement of three chromosomes and deleted chromosome13q.


In summary, we present a case with a novel rearrangement involving the important hematopoietic regulatory gene ETV6 in a case of pediatric primary AML. AEL is a rare subset of AML and a complex and variant t (7;12) with ETV6 rearrangement involving three chromosomes and loss of RB1 is a rare cytogenetic finding; this combination in pediatric primary de novo AEL and importance of the regulatory role of ETV6 gene in hematopoiesis is unique in the literature.



Conflict of interest

The author declares no conflict of interest.


Creative Commons Attribution License

©2016 Yenamandra, et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and build upon your work non-commercially.